LYEL (Lyell Immunopharma) Float Percentage Of Total Shares Outstanding: 85.65% (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LYEL Lyell Immunopharma Inc LYEL
55 GF Score
Price $13.19
GF Value $5.26
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Lyell Immunopharma Float Percentage Of Total Shares Outstanding?

Lyell Immunopharma LYEL +1.47% 55 Float Percentage Of Total Shares Outstanding is 85.65% as of Jul. 22, 2026. GuruFocus rates LYEL with a GF Score™ of 55/100 and a GF Value™ of $5.26 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Lyell Immunopharma's float shares is 20.99 Mil. Lyell Immunopharma's total shares outstanding is 24.50 Mil. Lyell Immunopharma's float percentage of total shares outstanding is 85.65%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Lyell Immunopharma's Insider Ownership is 22.13%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Lyell Immunopharma's Institutional Ownership is 62.23%.

LYEL
55GF Score
Lyell Immunopharma Inc LYEL
Float Percentage Of Total Shares Outstanding is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lyell Immunopharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Lyell Immunopharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=20.99/24.50
=85.65%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Float Percentage Of Total Shares Outstanding of 85.65% mean?
Lyell Immunopharma (LYEL) has a Float Percentage Of Total Shares Outstanding of 85.65% as of Jul. 22, 2026. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Lyell Immunopharma and its competitors.
Is Lyell Immunopharma's Float Percentage Of Total Shares Outstanding too high?
Lyell Immunopharma's current Float Percentage Of Total Shares Outstanding is 85.65%. Overall, Lyell Immunopharma has a GF Score™ of 55/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lyell Immunopharma's Float Percentage Of Total Shares Outstanding compare to ALXO and ARMP?
Lyell Immunopharma's Float Percentage Of Total Shares Outstanding of 85.65% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Float Percentage Of Total Shares Outstanding for a Biotechnology company?
A good Float Percentage Of Total Shares Outstanding depends on the Biotechnology industry context. However, Float Percentage Of Total Shares Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Float Percentage Of Total Shares Outstanding mean?
A high Float Percentage Of Total Shares Outstanding can signal that a stock is expensive relative to its fundamentals. Float percent of shares outstanding equals the percent of float shares relative to total shares. View historical data on Lyell Immunopharma and its competitors. Lyell Immunopharma's current Float Percentage Of Total Shares Outstanding is 85.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lyell Immunopharma stock overvalued right now?
Based on GuruFocus' analysis, Lyell Immunopharma (LYEL) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.26, compared to a current price of $13.19 — trading 150.8% above its estimated fair value. The current Float Percentage Of Total Shares Outstanding is 85.65%. Lyell Immunopharma's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Float Percentage Of Total Shares Outstanding calculated?
Float Percentage Of Total Shares Outstanding is calculated from a company's financial statements. For Lyell Immunopharma (LYEL), the current Float Percentage Of Total Shares Outstanding is 85.65% as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Lyell Immunopharma (LYEL) Overvalued in 2026?

Based on GuruFocus' analysis, Lyell Immunopharma stock appears to be overvalued. The current stock price of $13.19 is trading 150.8% above its estimated GF Value™ of $5.26. GuruFocus considers Lyell Immunopharma to be Significantly Overvalued.

Key valuation signals for LYEL:

  • Float Percentage Of Total Shares Outstanding: 85.65%
  • GF Value™: $5.26 vs. price of $13.19 (150.8% above fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the LYEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Lyell Immunopharma Business Description

Address 201 Haskins Way, South San Francisco, CA, USA, 94080
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.
55GF Score

Get the complete analysis for LYEL

Float Percentage Of Total Shares Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.19
Price
$5.26
GF Value